Key facts
- This page summarizes Naimish Patel's Form 4 filing for AgomAb Therapeutics NV (AGMB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Sep 2026, 16:06.
Naimish Patel - 11 Sep 2026 Form 4 Insider Report for AgomAb Therapeutics NV (AGMB)
- Reporting relationship
- Director
- Issuer ticker
- AGMB
- Reported as of
- 11 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2026, 16:06:19 UTC
- Prior SEC filing
- 02 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ellen Lefever, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Naimish Patel filed Form 4 for AgomAb Therapeutics NV (AGMB) on 15 Sep 2026.
Change
- Previous filing in this sequence was filed on 02 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002021679
Primary reporting owner
Patel Naimish
- Relationship
- Director
- Address
- AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM
- Signature
- /s/ Ellen Lefever, Attorney-in-Fact
- Signature date
- 15 Sep 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGMB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +56,328
- Change %
- Price
- $0.000000*
- Shares after
- 56,328
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 56,328
- Exercise price
- $13.94
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
Footnote F2
The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
Footnote F3
33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.